References
- Bhattacharjee, S., 2022. Craft of co-encapsulation in nanomedicine: a struggle to achieve synergy through reciprocity. ACS pharmacology and translational science, 5 (5), 278–298.
- Cahan, M.A., et al., 1994. Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer chemotherapy and pharmacology, 33 (5), 441–444.
- Caliskan, Y., et al., 2019. A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation. International journal of pharmaceutics, 557, 97–104.
- Campos, F.C., et al., 2014. Systemic toxicity induced by paclitaxel in vivo is associated with the solvent cremophor EL through oxidative stress-driven mechanisms. Food and chemical toxicology, 68, 78–86.
- Chatterjee, M., et al., 2017. Caveolae-mediated endocytosis is critical for albumin cellular uptake and response to albumin-bound chemotherapy. Cancer research, 77 (21), 5925–5937.
- Coors, E.A., et al., 2005. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Annals of allergy, asthma and immunology, 95 (6), 593–599.
- Das, V., and Miller, J.H., 2012. Non-taxoid site microtubule-stabilizing drugs work independently of tau overexpression in mouse N2a neuroblastoma cells. Brain research, 1489, 121–132.
- Dash, A.K., 2010. The dark side of paclitaxel. Oncology reviews, 4 (2), 71–72.
- Desai, N. P., et al., 2004. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof. United States Patent.
- Duan, R., et al., 2017. Polymer-lipid hybrid nanoparticles-based paclitaxel and etoposide combinations for the synergistic anticancer efficacy in osteosarcoma. Colloids and surfaces B, 159, 880–887.
- Eser, H., and Tihminlioglu, F., 2006. Determination of thermodynamic and transport properties of solvents and non solvents in poly(L-lactide-co-glycolide). Journal of applied polymer science, 102 (3), 2426–2432.
- Fellner, S., et al., 2002. Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. Journal of clinical investigation, 110 (9), 1309–1318.
- Filon, O., et al., 2017. A phase I study of safety and pharmacokinetics of NanoBB-1-Dox in patients with advanced solid tumors. Journal of clinical oncology, 35 (15 Suppl), e13537–e13537.
- Hahn, S.M., et al., 1993. Taxol in combination with doxorubicin or etoposide possible antagonism in vitro. Cancer, 72 (9), 2705–2711.
- Huang, T., et al., 2012. Synergistic increase in the sensitivity of osteosarcoma cells to thermochemotherapy with combination of paclitaxel and etoposide. Molecular medicine reports, 6 (5), 1013–1017.
- Kang, L., et al., 2015. Nanocarrier-mediated co-delivery of chemotherapeutic drugs and gene agents for cancer treatment. Acta pharmaceutica sinica B, 5 (3), 169–175.
- Kano, Y., et al., 1999. Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro. Cancer chemotherapy and pharmacology, 44 (5), 381–388.
- Kiya, K., et al., 1992. Penetration of etoposide into human malignant brain tumors after intravenous and oral administration. Cancer chemotherapy and pharmacology, 29 (5), 339–342.
- Kreuter, J., 2014. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Advanced drug delivery reviews, 71, 2–14.
- Kuhn, M., and von Wartburg, A., 1969. On a new glycoside synthesis process. II. Glycosides of 4’-demethylepipodophyllotoxins. Helvetica chimica acta, 52 (4), 948–957.
- Kumskova, N., et al., 2020. How subtle differences in polymer molecular weight affect doxorubicin-loaded PLGA nanoparticles degradation and drug release. Journal of microencapsulation, 37 (3), 283–295.
- Lagas, J.S., et al., 2010. P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clinical cancer research, 16 (1), 130–140.
- Leonard, A., and Wolff, J.E., 2013. Etoposide improves survival in high-grade glioma: a meta-analysis. Anticancer research, 33 (8), 3307–3315.
- Li, Y., et al., 2020. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug delivery, 27 (1), 1044–1053.
- Lidar, Z., et al., 2004. Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. Journal of neurosurgery, 100 (3), 472–479.
- Liederer, B.M., and Borchardt, R.T., 2006. Enzymes involved in the bioconversion of ester-based prodrugs. Journal of pharmaceutical sciences, 95 (6), 1177–1195.
- Lin, T., et al., 2016. Blood-brain-barrier-penetrating albumin nanoparticles for biomimetic drug delivery via albumin-binding protein pathways for antiglioma therapy. ACS nano. 10 (11), 9999–10012.
- Lipinski, C.A., et al., 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced drug delivery reviews, 46 (1-3), 3–26.
- van de Loosdrecht, A.A., et al., 1994. A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. Journal of immunological methods, 174 (1–2), 311–320.
- Mahira, S., et al., 2019. Cabazitaxel and silibinin co-encapsulated cationic liposomes for CD44 targeted delivery: A new insight into nanomedicine based combinational chemotherapy for prostate cancer. Biomedicine and pharmacotherapy, 110, 803–817.
- Maier, R., et al., 2021. Human versus bovine serum albumin: a subtle difference in hydrophobicity leads to large differences in bulk and interface behavior. Crystal growth and design, 21 (9), 5451–5459.
- Maksimenko, O., et al., 2019. Doxorubicin-loaded PLGA nanoparticles for the chemotherapy of glioblastoma: towards the pharmaceutical development. International journal of pharmaceutics, 572, 118733.
- Maleki, H., et al., 2021a. Effect of paclitaxel/etoposide co-loaded polymeric nanoparticles on tumor size and survival rate in a rat model of glioblastoma. International journal of pharmaceutics, 604, 120722.
- Maleki, H., et al., 2021b. Preparation of paclitaxel and etoposide co-loaded mPEG-PLGA nanoparticles: an investigation with artificial neural network. Journal of pharmaceutical innovation, 16 (1), 11–25.
- Mendes, L.P., Pan, J., and Torchilin, V.P., 2017. Dendrimers as nanocarriers for nucleic acid and drug delivery in cancer therapy. Molecules, 22 (9), 1401–1421.
- Montecucco, A., Zanetta, F., and Biamonti, G., 2015. Molecular mechanisms of etoposide. EXCLI journal, 14, 95–108.
- Moya, E., et al., 2022. Interaction of surfactant coated PLGA nanoparticles with in vitro human brain-like endothelial cells. International journal of pharmaceutics, 621, 121780.
- Neil, I., and Desai, I., 2007. Nab technology: a drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor-derived SPARC for targeting. Drug delivery report, 16, 37–41.
- Ohnuma, T., et al., 1992. Preparation and antitumor activity of 2’’-O-, 3’’-O- and 2’’,3’’-di-O-substituted derivatives of etoposide. Chemical & pharmaceutical bulletin, 40 (7), 1783–1788.
- Palmer, A.C. and Sorger, P.K., 2017. Combination cancer therapy can confer benefit via patient-to-patient variability without drug additivity or synergy. Cell, 171 (7), 1678–1691.e13. e13.
- Pan, J., et al., 2019. Polymeric co-delivery systems in cancer treatment: an overview on component drugs’ dosage ratio effect. Molecules, 24 (6), 1035–1066.
- Pereverzeva, E., et al., 2019. Toxicological study of doxorubicin-loaded PLGA nanoparticles for the treatment of glioblastoma. International journal of pharmaceutics, 554, 161–178.
- Perez, C., Daniel, K.B., and Cohen, S.M., 2013. Evaluating prodrug strategies for esterase-triggered release of alcohols. ChemMedChem. 8 (10), 1662–1667.
- Perez, E.A., Buckwalter, C.A., and Reid, J.P., 1996. Combinations of paclitaxel and etoposide in the treatment of lung cancer. Seminars in oncology, 6 (15), 21–25.
- Ramón Y Cajal, S., et al., 2020. Clinical implications of intratumor heterogeneity: challenges and opportunities. Journal of molecular medicine, 98 (2), 161–177.
- Reck, M., et al., 2003. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. Journal of the national cancer institute, 95 (15), 1118–1127.
- Sarisozen, C., et al., 2017. Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors. Journal of pharmaceutical investigation, 47 (1), 37–49.
- Siestma, H., et al., 2000. 1-Phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for Taxol and vincristine. Clinical cancer research, 6 (3), 942–948.
- Sriraman, S.K., et al., 2016. Enhanced cytotoxicity of folic acid-targeted liposomes co-loaded with C6 ceramide and doxorubicin: in vitro evaluation on HeLa, A2780-ADR, and H69-AR cells. Molecular pharmaceutics, 13 (2), 428–437.
- Tan, A.C., et al., 2020. Management of glioblastoma: state of the art and future directions. CA: a cancer journal for clinicians, 70 (4), 299–312.
- Veber, D.F., et al., 2002. Molecular properties that influence the oral bioavailability of drug candidates. Journal of medicinal chemistry, 45 (12), 2615–2623.
- Wang, B., et al., 2015a. Paclitaxel and etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. Journal of nanobiotechnology, 13 (1), 22–32.
- Wang, Z., et al., 2015b. Development of etoposide-loaded bovine serum albumin nanosuspensions for parenteral delivery. Drug delivery, 22 (1), 79–85.
- Weaver, B.A., 2014. How taxol/paclitaxel kills cancer cells. Molecular biology of the cell, 25 (18), 2677–2681.
- Weiszhár, Z., et al., 2012. Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20. European journal of pharmaceutical sciences, 45 (4), 492–498.
- Wu, D., et al., 2020. Design principles of drug combinations for chemotherapy. Journal of controlled release, 323, 36–46.
- Xu, Z., et al., 2015. Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy. Nanoscale, 7 (13), 5859–5868.
- Yardley, D.A., 2013. Drug resistance and the role of combination chemotherapy in improving patient outcomes. International journal of breast cancer, 2013, 1–15.
- Yi, X., et al., 2015. Co-delivery of pirarubicin and paclitaxel by human serum albumin nanoparticles to enhance antitumor effect and reduce systemic toxicity in breast cancers. Molecular pharmaceutics, 12 (11), 4085–4098.
- Zensi, A., et al., 2009. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. Journal of controlled release, 137 (1), 78–86.
- Zhang, D.Y., et al., 2020. Ultrasound-mediated delivery of paclitaxel for glioma: a comparative study of distribution, toxicity, and efficacy of albumin-bound versus cremophor formulations. Clinical cancer research, 26 (2), 477–486.
- Zhang, L., et al., 2013. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clinical cancer research, 19 (21), 5972–5983.